Early rheumatoid factor decline predicts subsequent clinical remission in rheumatoid arthritis: the ANSWER cohort

Clicks: 18
ID: 328152
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #173 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: To compare early changes in rheumatoid factor (RF) across classes of biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) and assess whether early RF decline was associated with 12-month clinical remission in rheumatoid arthritis (RA). METHODS: We retrospectively analysed 1,423 newly initiated b/tsDMARD treatment courses from the multicentre ANSWER cohort that continued for ≥12 months and had RF measured at baseline and 3 months. Early RF decline was defined as a ≥ 20% reduction at 3 months. Multivariable regression assessed factors associated with RF change and 12-month Clinical Disease Activity Index (CDAI) remission. Twelve-month remission rates were also compared across four categories of RF reduction. RESULTS: RF reduction differed across classes, with Janus kinase inhibitors (JAKi) showing the greatest decline. Compared with tumour necrosis factor inhibitors (TNFi), JAKi were associated with a greater RF reduction (β = -14.50, 95% CI - 20.04 to - 8.97; P < 0.001). The direction was similar in multiple sensitivity analyses and remained significant in propensity score-matched analyses. Early RF decline was independently associated with 12-month CDAI remission (adjusted OR 1.39, 95% CI: 1.04-1.88; P = 0.029). A significant overall trend towards higher 12-month remission rates was observed across categories of greater RF reduction (P for trend = 0.004). CONCLUSIONS: Early RF decline differed across b/tsDMARD classes and was associated with 12-month remission. Longitudinal RF dynamics may provide clinically useful prognostic information in RA.
Reference Key
openalex_W7212034536 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kenya Sugimoto, Ryu Watanabe, Yuya Fujita, Takayuki Fujii, Akira Onishi, Yuji Nozaki, Tetsu Itami, Kosuke Ebina, Yuki Etani, Hirotaka Yamada, Sho Sendo, Akihiro Tanaka, Hideki Amuro, Ayaka Yoshikawa, Takuya Kotani, Masaki Katayama, Wataru Yamamoto, Ryuhei Ishihara, Masao Katsushima, Kazuo Fukumoto, Shinsuke Yamada, Motomu Hashimoto
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag498
URL
https://doi.org/10.1093/rheumatology/keag498
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.